These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 38979083)

  • 1. Prognostic Value of Alpha-Fetoprotein in Unresectable Hepatocellular Carcinoma Treated with Hepatic Artery Infusion Chemotherapy Combined with Lenvatinib and Camrelizumab.
    Xiao Y; Chen W; Deng W; Zhu G; Xie J; Luo L; Lin L; Tao J; Hu Z; Shan R
    J Hepatocell Carcinoma; 2024; 11():1251-1263. PubMed ID: 38979083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pretreatment Neutrophil-to-Lymphocyte Ratio as Prognostic Biomarkers in Patients with Unresectable Hepatocellular Carcinoma Treated with Hepatic Arterial Infusion Chemotherapy Combined with Lenvatinib and Camrelizumab.
    Xiao Y; Zhu G; Xie J; Luo L; Deng W; Lin L; Tao J; Hu Z; Shan R
    J Hepatocell Carcinoma; 2023; 10():2049-2058. PubMed ID: 37965074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatic Arterial Infusion Chemotherapy Combined Lenvatinib and PD-1 Inhibitor Showed Improved Survival for Infiltrative Hepatocellular Carcinoma: A Multicenter Cohort Study.
    Li R; Wang X; Li H; Wang M; Wang J; Wang W; Zhou Q
    J Hepatocell Carcinoma; 2024; 11():1727-1740. PubMed ID: 39281003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lenvatinib Plus Camrelizumab vs. Lenvatinib Monotherapy as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Cohort Study.
    Li Q; Cao M; Yuan G; Cheng X; Zang M; Chen M; Hu X; Huang J; Li R; Guo Y; Ruan J; Chen J
    Front Oncol; 2022; 12():809709. PubMed ID: 35280760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early Alpha-Fetoprotein Response Is Associated With Survival in Patients With HBV-Related Hepatocellular Carcinoma Receiving Lenvatinib.
    Liu B; Shang X; Shi JY; Cui GZ; Li X; Wang NY
    Front Oncol; 2022; 12():807189. PubMed ID: 35251977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early Tumor Marker Response Predicts Treatment Outcomes in Patients with Unresectable Hepatocellular Carcinoma Receiving Combined Lenvatinib, Immune Checkpoint Inhibitors, and Transcatheter Arterial Chemoembolization Therapy.
    Luo MC; Wu JY; Wu JY; Lin ZT; Li YN; Zeng ZX; Wei SM; Yan ML
    J Hepatocell Carcinoma; 2023; 10():1827-1837. PubMed ID: 37850079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overall survival and objective response in advanced unresectable hepatocellular carcinoma: A subanalysis of the REFLECT study.
    Kudo M; Finn RS; Qin S; Han KH; Ikeda K; Cheng AL; Vogel A; Tovoli F; Ueshima K; Aikata H; López CL; Pracht M; Meng Z; Daniele B; Park JW; Palmer D; Tamai T; Saito K; Dutcus CE; Lencioni R
    J Hepatol; 2023 Jan; 78(1):133-141. PubMed ID: 36341767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Postprogression treatment of lenvatinib plus PD-1 inhibitor in advanced hepatocellular carcinoma refractory to hepatic arterial infusion chemotherapy.
    An C; Fu Y; Li W; Zuo M; Wu P
    Cancer; 2023 Jul; 129(14):2235-2244. PubMed ID: 37029486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early α-fetoprotein response as a predictor for clinical outcome after localized concurrent chemoradiotherapy for advanced hepatocellular carcinoma.
    Kim BK; Ahn SH; Seong JS; Park JY; Kim DY; Kim JK; Lee DY; Lee KH; Han KH
    Liver Int; 2011 Mar; 31(3):369-76. PubMed ID: 21083802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative Analysis of Lenvatinib and Hepatic Arterial Infusion Chemotherapy in Unresectable Hepatocellular Carcinoma: A Multi-Center, Propensity Score Study.
    Lee J; Han JW; Sung PS; Lee SK; Yang H; Nam HC; Yoo SH; Lee HL; Kim HY; Lee SW; Kwon JH; Jang JW; Kim CW; Nam SW; Oh JS; Chun HJ; Bae SH; Choi JY; Yoon SK
    J Clin Med; 2021 Sep; 10(18):. PubMed ID: 34575160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toripalimab Combined With Hepatic Arterial Infusion Chemotherapy Versus Lenvatinib for Advanced Hepatocellular Carcinoma.
    Xu YJ; Lai ZC; He MK; Bu XY; Chen HW; Zhou YM; Xu L; Wei W; Zhang YJ; Chen MS; Guo RP; Shi M; Li QJ
    Technol Cancer Res Treat; 2021; 20():15330338211063848. PubMed ID: 34898313
    [No Abstract]   [Full Text] [Related]  

  • 12. Survival Benefit of Lenvatinib Plus PD-1 Inhibitor with or Without HAIC in Advanced Hepatocellular Carcinoma Beyond Oligometastasis: a Multicenter Cohort Study.
    Wang M; Zhou Q; Li H; Liu M; Li R; Wang W; Wang X; Huang J; Duan F
    Immunotargets Ther; 2024; 13():447-459. PubMed ID: 39280092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TACE combined Lenvatinib plus Camrelizumab versus TACE alone in efficacy and safety for unresectable hepatocellular carcinoma: a propensity score-matching study.
    Tang Z; Bai T; Wei T; Wang X; Chen J; Ye J; Li S; Wei M; Li X; Lin Y; Tang J; Li L; Wu F
    BMC Cancer; 2024 Jun; 24(1):717. PubMed ID: 38862932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis on Efficacy of Hepatic Artery Infusion Chemotherapy with or without Lenvatinib for Unresectable Hepatocellular Carcinoma.
    Yuan W; Yue W; Wen H; Wang X; Wang Q
    Eur Surg Res; 2023; 64(2):268-277. PubMed ID: 36812900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of alpha-fetoprotein and neutrophil-to-lymphocyte ratio to predict treatment response and survival outcomes of patients with unresectable hepatocellular carcinoma treated with immune checkpoint inhibitors.
    Zhu HF; Feng JK; Xiang YJ; Wang K; Zhou LP; Liu ZH; Cheng YQ; Shi J; Guo WX; Cheng SQ
    BMC Cancer; 2023 Jun; 23(1):547. PubMed ID: 37322411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatic arterial infusion chemotherapy, lenvatinib plus programmed cell death protein-1 inhibitors: A promising treatment approach for high-burden hepatocellular carcinoma.
    Fu S; Xu Y; Mao Y; He M; Chen Z; Huang S; Li D; Lv Y; Wu J
    Cancer Med; 2024 May; 13(9):e7105. PubMed ID: 38686567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modified Hepatic Arterial Infusion Chemotherapy Combined with Lenvatinib and Camrelizumab for Advanced HCC: Two Case Reports.
    Tian Y; Jin W; Sun H; Jin D; Kang D; Li Z; Piao L
    J Hepatocell Carcinoma; 2023; 10():1587-1593. PubMed ID: 37791067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early on-treatment predictions of clinical outcomes using alpha-fetoprotein and des-gamma-carboxy prothrombin responses in patients with advanced hepatocellular carcinoma.
    Lee MH; Kim SU; Kim DY; Ahn SH; Choi EH; Lee KH; Lee DY; Seong J; Han KH; Chon CY; Park JY
    J Gastroenterol Hepatol; 2012 Feb; 27(2):313-22. PubMed ID: 21793906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does first-line treatment have prognostic impact for unresectable HCC?-Atezolizumab plus bevacizumab versus lenvatinib.
    Hiraoka A; Kumada T; Tada T; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Hatanaka T; Kakizaki S; Shimada N; Kawata K; Naganuma A; Kosaka H; Shibata H; Aoki T; Tanaka T; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Koizumi Y; Nakamura S; Joko K; Iijima H; Kaibori M; Hiasa Y; Kudo M;
    Cancer Med; 2023 Jan; 12(1):325-334. PubMed ID: 35666040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors versus lenvatinib and PD-1 inhibitors for HCC refractory to TACE.
    Diao L; Wang C; You R; Leng B; Yu Z; Xu Q; Cheng Y; Yin G
    J Gastroenterol Hepatol; 2024 Apr; 39(4):746-753. PubMed ID: 38240156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.